daily oral glp-1 receptor agonist orforglipron for adults with obesity Orforglipron, an Small-Molecule Treatment In the ATTAIN-1 phase 3,
Description
As shown in Scheme 26
[DOI] [PubMed] [Google Scholar] 928.Nauck M.A., Bartels E., Orskov C., Ebert R., Creutzfeldt W
Dosage Timing If youre thinking about trying the new weight loss pill instead of the weekly injection, you may need to rethink your morning routine
2013;304(2):F137F144
Immunoglobulin Fc heterodimer platform technology: from design to applications in therapeutic antibodies and proteins
Dandona P, Mathieu C, Phillip M et al (2018) Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study
